WHERE ARE YOU?

Concept Pre-Sub Submission prep Newly cleared Raising Exit Postmarket & security

THE TAPE

FDA makes the Draeger VentStar Resus Neo hose removal a Class I recall Control Bionics wins a Class I CE mark for the NeuroStrip muscle sensor Medicare starts paying for Carlsmed Aprevo lumbar fusion under three new codes ABK Biomedical breaks ground on a Missouri plant for its Y90 microspheres Boston Scientific releases the last $8M from Elutia's BioEnvelope sale BlueWind gets a Category I CPT code for subfascial tibial neuromodulation Emboline runs its first US commercial Emboliner cases at Columbia SedMed raises $4M for a toilet lift that runs without power CDRH plans 11 final guidances in FY2027 and puts AI lifecycle management first FDA makes the Draeger VentStar Resus Neo hose removal a Class I recall Control Bionics wins a Class I CE mark for the NeuroStrip muscle sensor Medicare starts paying for Carlsmed Aprevo lumbar fusion under three new codes ABK Biomedical breaks ground on a Missouri plant for its Y90 microspheres Boston Scientific releases the last $8M from Elutia's BioEnvelope sale BlueWind gets a Category I CPT code for subfascial tibial neuromodulation Emboline runs its first US commercial Emboliner cases at Columbia SedMed raises $4M for a toilet lift that runs without power CDRH plans 11 final guidances in FY2027 and puts AI lifecycle management first

Acquisition

GE HealthCare pays $945M cash for Sofie Biosciences and 15 PET manufacturing sites

MedDevice Startups Staff · 23 hrs ago · 2 min read · Via MedTech Dive

GE HealthCare agreed to buy Sofie Biosciences for $945 million in cash. The companies announced the deal on October 5. It is expected to close in the first half of 2027.

Sofie runs 15 contract manufacturing sites across the United States and already makes GE HealthCare's Flyrcado, a flurpiridaz F18 injection. F18 tracers decay with a 110 minute half life, so a dose has to be produced close to the scanner that will use it. The site count is the asset in this deal.

The purchase also hands GE HealthCare US rights to FAPI-74, a pan-cancer PET tracer in Phase 3. GE HealthCare already held the rights outside the US. Sofie joins the pharmaceutical diagnostics business and stays an independent manufacturing partner to its other customers. GE HealthCare expects the unit to grow in the low double digits and to add to revenue growth, adjusted EBIT margin and adjusted earnings per share in the first full year of ownership.

Questions & Answers

How much is GE HealthCare paying for Sofie Biosciences?

GE HealthCare is paying $945 million in cash for Sofie Biosciences. The companies announced the deal on October 5, 2026.

When will the GE HealthCare acquisition of Sofie Biosciences close?

GE HealthCare expects the Sofie Biosciences acquisition to close in the first half of 2027.

What does Sofie Biosciences do?

Sofie Biosciences is a contract manufacturer of PET radiopharmaceuticals with 15 sites across the United States. It already makes GE HealthCare's Flyrcado flurpiridaz F18 injection.

← Back to M&A